CD206 Flow Cytometry Antibody: The Macrophage That Touches Regenerating Alveoli
Idiopathic pulmonary fibrosis kills about half of the people it is diagnosed in within five years, and current drugs only slow the decline. The unresolved question is not why scar forms. It is why the alveolus keeps trying to rebuild itself and keeps producing the wrong tissue.
A recent spatial atlas of human lung gives that question a cellular address. Its central finding is a physical association between one macrophage subset and one abnormal epithelial state, and the marker that names the macrophage is CD206.
What the Atlas Actually Measured
The study is the largest single-cell spatial survey of regenerating alveoli in fibrotic human lung. Its design is worth stating precisely, because the claim rests on the sampling.
| Parameter | Detail |
|---|---|
| Tissue | explants from 7 IPF patients undergoing transplant, each sampled at early, mid and late fibrotic regions |
| Controls | lung tissue from 2 healthy donors |
| Platform | 33-plex imaging mass cytometry with a custom spatial pipeline |
| Area analysed | 61.89 mm² of intact lung architecture |
| Cells resolved | 313,818 single cells |
| Clusters | 29, comprising 12 structural and 17 immune populations |
Because every cell keeps its coordinates, the dataset supports a claim that dissociation-based single-cell work cannot make. Two populations can be shown to touch.
The Epithelium Is Regenerating, and Doing It Wrong
Healthy alveolar repair depends on alveolar stem cells differentiating into functional epithelial cells. In the IPF regenerating niche that output is inverted. Abnormal alveolar basal intermediate cells and basal cells together exceed 64% of the epithelial compartment, while functional type I alveolar epithelial cells fall below 5%. In healthy lung the ratio of type I to type II alveolar epithelial cells is 2:1.
The intermediate cells resolve into three subsets, ABI_a, ABI_b and ABI_b-DC ADJ. Protein markers and transcriptomes place all three on an abnormal differentiation trajectory that ends in the honeycomb cyst, the non-functional structure that defines end-stage disease.
The timing is the uncomfortable part. Even in late-stage tissue, where collagen deposition peaks and fibroblast foci are sparse, ABI cells remain abundant. The epithelium is attempting regeneration throughout the disease. It simply never completes it correctly.
One Immune Population Passes the Spatial Test
Healthy lung carries little immune infiltration. Every fibrotic stage sampled here carries a large infiltrate. It is dominated by CD14-low monocytes, CD4 T cells, CD8 T cells and CD206 macrophages, and the composition does not shift significantly between stages.
Abundance is not association, so the authors used an unbiased mathematical test of spatial relationships. CD206-high macrophages were the only immune population with a statistically significant spatial association with alveolar epithelium at every disease stage. The tightest pairing was with the ABI_b-DC ADJ subset.
The other populations behave differently. CD103+ CD4 T cells associate with ABI only in early disease. Neutrophils and NK cells correlate in number with ABI at mid-stage but show no direct spatial association. A three-way analysis puts CD206-high or CD206-mid macrophages, ABI_b-DC ADJ and the fibrotic front together as the strongest connected niche in mid-stage tissue.
Contact analysis adds the final piece. CD206-high macrophages make direct physical contact with ABI, at all stages, and they are the only immune cell type that does so.
Domain architecture of CD206, showing the cysteine-rich domain, fibronectin type II domain, eight C-type lectin-like domains, the transmembrane segment and the intracellular domain
The Receptor Behind the Marker
CD206 is a multidomain receptor, and its architecture explains why it marks this subset rather than any macrophage. The extracellular portion carries a cysteine-rich domain, a fibronectin type II domain and eight C-type lectin-like domains, followed by a transmembrane segment and a short intracellular tail.
The lectin domains bind carbohydrate structures, which is the classical mannose-receptor function. The fibronectin type II domain binds collagen and gelatin. A cell displaying this combination can engage matrix and glycosylated ligands at the same time. That is exactly the phenotype the spatial data demands of a cell sitting on a remodeling surface.
Two Signals That Close the Loop
Receptor-ligand analysis of the single-cell transcriptomes identified a specific exchange between the two partners, and it runs in both directions.
From macrophage to epithelium, fibronectin secreted by CD206-high macrophages engages integrins and syndecans on ABI. The fibronectin-integrin axis is a classical fibrosis pathway; it activates TGF-beta and other profibrotic cytokines and pushes ABI toward a basal fate.
From epithelium to macrophage, ABI secretes macrophage migration inhibitory factor, which binds CD74-CD44 and CD74-CXCR4 complexes on the macrophage. MIF signaling sustains the pro-inflammatory state and suppresses apoptosis, so the macrophage persists and the niche stays inflamed. The two directions together form a loop in which abnormal regeneration feeds inflammation and inflammation feeds abnormal regeneration.
A Subset That Is Neither FABP4 nor SPP1
The population is new. It is distinct from the FABP4+ resident macrophages and the SPP1+ profibrotic macrophages already described in IPF, and its defining functional marker is high fibronectin expression.
That distinction matters for anyone designing a panel. A CD206 stain alone will capture several macrophage states. Separating this subset requires CD206 together with the markers that exclude the known populations, and the fibronectin signal is what identifies it functionally.
From Atlas to Panel
Four readouts follow directly from the study, and each uses the antibody differently.
| Readout | Combination | Question answered |
|---|---|---|
| Subset proportion | CD206, CD14, CD64 | how much of the myeloid compartment is CD206-high |
| Monocyte versus macrophage | CD14, CD64, CD206 | where the boundary sits in a digest |
| Sorted population profiling | CD206 sort, then RNA sequencing | whether the sorted cells carry the fibronectin program |
| Treatment monitoring | CD206, CD206-low fraction | whether an intervention shifts subset balance |
Two practical cautions belong here. CD206 is also expressed on immature dendritic cells and on some endothelial cells, so a myeloid gate should precede the CD206 read. And because the atlas claim is spatial, a dissociation-based percentage is a weaker instrument for testing it; imaging or spatial methods carry the original evidence.
| Cat. No. | Product Name | Application | Purchase |
|---|---|---|---|
| S0B1823 | FITC Mouse Anti-Human CD206 Antibody (15-2) | direct surface staining in multicolor panels | |
| S0B1316 | Mouse Anti-Human CD206 Antibody (15-2) | secondary detection, sorting, blockade |
Both reagents are supplied for research use only and are not intended for diagnostic or therapeutic procedures.
What the Finding Does Not Say
The atlas establishes association, not causation. Contact between a macrophage and an epithelial cell is consistent with instruction, but it is also consistent with a macrophage being recruited to a dying cell.
The therapeutic implications are nevertheless concrete, and the authors name three. Target the CD206-high macrophage, interrupt the fibronectin-integrin and MIF-CD74 axes, and note that late-stage tissue still contains regenerating epithelium.
Conclusion
Pulmonary fibrosis has been described as a disease of failed repair without a map of the failure. The spatial atlas supplies one, and the address it gives is a CD206-high macrophage in direct contact with an abnormal basal intermediate cell. A flow cytometry antibody is a coarse instrument next to that map, but it is the instrument that turns the finding into a sortable, countable population.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
ANT BIO PTE. LTD. supplies high-quality reagents and solutions for life science research. Our sub-brands cover the full research workflow: Starter for antibodies and immunological assay kits, UA-Bio for recombinant proteins and drug discovery solutions, and Absin for general reagents and other detection kits. Explore our product portfolio at www.antbioinc.com.
